Jump to:

Product Design

Memo (re: report on the psychopharmacological effects of the N'-substituted nicotine analogues)

Date: 16 Mar 1983
Length: 2 pages
1000127513-7514
Jump To Images
snapshot_pm 1000127513-1000127514

Abstract

Memo describes results of a study on psychopharmacologic effects of N'-substituted nicotine analogues. Compunds were found to produce mild sedation and muscle relaxation in rats, although not depressants, and "might be of value in anxiety-related depression. Recommedation to consider applying for patents for this chemically unique class of compounds.

Fields

Rank
1
Author
ABOOD, LG
Hypothesis
Health effects
Design changes which have measurably altered health effects of cigarette smoke, both for smokers and nonsmokers.
Nicotine transport, transfer, and uptake
Design changes which alter nicotine delivery or effect how the product causes and maintains dependence, including transfer of nicotine from tobacco to smoke, and uptake into the body.
Keyword
Depressants
Muscle relaxant
Psychotherapeutic
Tranquilizers
Additive
N'-substituted nicotine analogues
Smoke Constituent
Benzodiazepines
Subject
CNS/Brain (Effects)
nicotine technology
nicotine analogues (Technology)
Pharmacology (Effects)

Document Images

Text Control

Highlight Text:

OCR Text Alignment:

Image Control

Image Rotation:

Image Size:

Page 1: wvc08e00
~. March 16, 1983 T. S. Osdene, Ph.D. Director of Research Philip Morris Research Center P.O. Box 26583 Richmond, Virginia 23261 Dear Tom: Enclosed is a report on the psychopharmacologic effects of the N'- substituted nicotine analogues. The drugs definitely appear to be tranquilizers, producing mild sedation and muscle relaxation (in rats). Although they are not as potent as the benzodiazepines (e.g. valium) they could conceivably have anti-anxiety effects. Furthermore, they are not depressants and might be of value in anxiety-related depression. For comparative purposes data are presented for valium. The preliminary tests involving only the assessment of overt behavior following IP and intraventricular adminsitration. When more material is available we can determine its anti-reserpine effect, prolongation in barbit- urate sleeping time, interacting with catecholaminergic systems, etc. You may wan,t to consider applying for patent for this class of compounds, since they are chemically unique and may possess some novel psychotherapeutic effects. Perhaps we can discuss this matter further at my next visit April 12, 13, 1983. Enclosed are abstracts of a ACNP meeting that may be of interest to you. Sincerely, ~;F" Leo G. Abood LGA:ca ~.~ ~ W.
Page 2: wvc08e00
- CR # Structure Dose (IP) mg/kg Sedation Body Tone Tranquilization (IVC) 50 pg ~o~~ ~ ~ ~,CK3 5 + + 2226 ~ 10 ++ + ++f~: 20 +++ ++ C 10 + + 2229 N'~ ~N 20 ++ ++ ~~ '~- ~-~ 10 + + - 2233 ~,1 o ~CHj 20 + + 7ZT ~ ~---- , 10 . 0 0 2228 fC , `t4 20 + 0 4+.+ ~l 10 0 0 2213 ~n ~ hl~{, 20 + 0 ~ ~ ~ 10 + 0 2250 ~~',~~. ~ ~. ~ 20 • ++ ++ ~ , 10 - 0 0 20 ++ + 4+ 1g _l 0 0 + 2282 - C0 ~ ~o ' N ~f~~ 2 + + Tranquilizing effects of various CR compounds in ra $ after intraperitoneal and intraventricular administration. ~000127514 "Sedation" was determined by measuring locomotion in an open field maze and the response to noxious (air blast) stimuli. "Body time" was estimated by handling rats and ability to hang from a rotor-bar. "Tranquilization" after IVC injection was estimated from muscle weakness in all four limbs, body tone, an& general activity. Rating scale was 0 - l+H. For comparative purposes, a dose of 5 mg/kg valium (IP) will have ++F+ in sedation and body tone, while 10 wg IVC will have a f+F+ in tranquilization. The duration of action of the CR drugs was 10-20 minutes IVC and about 30 minutes after IP injecti'on.

Text Control

Highlight Text:

OCR Text Alignment:

Image Control

Image Rotation:

Image Size: